Notal Vision will provide home OCT monitoring services to support the CONGO and SHASTA phase 1 trials studying AsclepiX’s AXT107 in patients with retinal diseases, according to a press release.
The partnership will augment the phase 1 clinical trial data by contributing data points obtained by study patients at home between scheduled clinic visits.
Patients with diabetic macular edema and age-related macular will use the Notal Home OCT device daily, imaging data will be transmitted to the secure Notal Health Cloud, and the Notal OCT Analyzer will quantify intraretinal and subretinal fluid
Uncategorized